Endologix Reports Positive Clinical Data from the Ovation LUCY Study with 1.3% Major Adverse Event
June 01, 2017 at 04:19 AM EDT
Endologix, Inc. (NASDAQ: ELGX) announced Wednesday, 30-day results from the LUCY (Evaluation of FemaLes who are Underrepresented ...
